GB2424270A - Optical monitoring of predetermined substances in blood - Google Patents
Optical monitoring of predetermined substances in blood Download PDFInfo
- Publication number
- GB2424270A GB2424270A GB0505101A GB0505101A GB2424270A GB 2424270 A GB2424270 A GB 2424270A GB 0505101 A GB0505101 A GB 0505101A GB 0505101 A GB0505101 A GB 0505101A GB 2424270 A GB2424270 A GB 2424270A
- Authority
- GB
- United Kingdom
- Prior art keywords
- blood
- light
- substance
- level
- reference spectrum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008280 blood Substances 0.000 title claims abstract description 84
- 210000004369 blood Anatomy 0.000 title claims abstract description 84
- 239000000126 substance Substances 0.000 title claims abstract description 40
- 238000012544 monitoring process Methods 0.000 title claims abstract description 28
- 230000003287 optical effect Effects 0.000 title claims 2
- 238000001228 spectrum Methods 0.000 claims abstract description 49
- 230000003595 spectral effect Effects 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 32
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000002835 absorbance Methods 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 abstract description 13
- 239000001301 oxygen Substances 0.000 abstract description 13
- 238000012886 linear function Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 21
- 238000005259 measurement Methods 0.000 description 19
- 238000000862 absorption spectrum Methods 0.000 description 17
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000008033 biological extinction Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 238000006213 oxygenation reaction Methods 0.000 description 7
- 238000010420 art technique Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 239000006096 absorbing agent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000013307 optical fiber Substances 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009429 electrical wiring Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 238000000411 transmission spectrum Methods 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Apparatus and method for monitoring predetermined substances such as oxygen in blood. In order to monitor blood oxygen saturation (SO2), light is directed onto a target area of a patient's skin and light that has either been reflected by or transmitted through blood in the target area is detected by a spectrometer. A first reference spectrum 10 is obtained corresponding to blood of low oxygen saturation and a second reference spectrum 11 is obtained corresponding to blood of high oxygen saturation. A third reference spectrum is obtained corresponding to changes in the spectral content of the detected light due to one or more other factors, such as the melanin of the patient's skin. The total melanin contribution may be modelled as a linear function of wavelength. A set of coefficients is then calculated relating the spectral content of the detected light to the first, second and third reference spectral values relatively weighted by the coefficients. Oxygen saturation is determined from the ratio of the coefficients relating to the first and second spectra.
Description
M&C Folio No P53352GB 1 Monitoring of Predetermined Substances in Blood
This invention relates to apparatus and methods for monitoring the level of a predetermined substance, such as oxygen, in blood. The invention may employ invasive or non-invasive measurement techniques, and is suitable for determining blood oxygen saturation in patients in any context, for example central venous SO2 monitoring, pulmonary artery 502 monitoring, extracorporeal SO2 monitoring, amputation level assessment and free-flap SO2 monitoring, for example.
The standard way to measure blood oxygen saturation in a patient is to direct light onto a target area of the patient's body containing the blood, and to measure the intensity of light reflected by or transmitted through the blood in the target area, either at discreet wavelengths or over a substantially continuous spectral range, and then to calculate the SO2 as a function of the measured light intensity values. Such measurement apparatus is known from WO 94/03102 for example. However many factors reduce the accuracy of such known SO2 measurement apparatus. One significant factor is the degradation of the accuracy of the apparatus due to patient movement, that is due to motion that leads to a change in the path length of the light through the biological tissue and hence to variation in the intensity of the detected light. This problem is particularly severe in critical health care applications where continuous monitoring is essential. Another factor that reduces the accuracy of such measurement apparatus is skin pigmentation, in that, for measurements made at the patient's skin, the quantity of detected light will vary depending on skin colour which ranges from fair to dark as the concentration of melanin increases.
Furthermore WO 00/09004 describes SO2 measurement apparatus that operates by passing light through biological tissue and monitoring the transmitted or reflected light continuously by means of a photodetector. However, the subsequent analysis of the detected light is based on the use of only a limited number of wavelengths, including some isobestic wavelengths at which oxygenated blood and deoxygenated blood absorb the same amount of light. The fact that only a limited number of wavelengths are used in such analysis in such apparatus limits the accuracy of the SO2 determination.
M&C Folio No P53352GB 2 Furthermore the apparatus is sensitive to ambient light interference, for example due to the use of fluorescent lighting.
Furthermore WO 00/01294 describes apparatus for measuring one or more analytes in blood in a patient's body which comprises a light transmitter comprising a plurality of transmitting fibres positioned to transmit light to the body, and a light detector comprising a plurality of light detector fibres positioned to detect light transmitted through or reflected from the body. Light of only certain discreet wavelengths, including some of the isobestic wavelengths, is transmitted to and reflected from the blood, and accordingly such apparatus also suffers from limited accuracy and is sensitive to ambient interference.
It is an object of the invention to provide apparatus and methods for monitoring the level of a predetermined substance in blood that is of inherently greater accuracy in use.
According to one aspect of the present invention there is provided apparatus for monitoring the level of a predetermined substance in blood, comprising a light source for directing light onto a target area; a detector for detecting light from the source that has been reflected by or transmitted through blood in the target area; and an analyser for analysing the spectral content of the detected light, the analyser comprising first memory means for storing values representative of a first reference spectrum corresponding to a relatively low level of said substance in the blood, second memory means for storing values representative of a second reference spectrum corresponding to a relatively high level of said substance in the blood, third memory means for storing values representative of a third reference spectrum corresponding to changes in the spectral content of the detected light due to one or more factors other than the level of said substance in the blood, calculating means for calculating a set of coefficients relating the spectral content of the detected light to the first, second and third reference spectrum values relatively weighted by the coefficients, and determining means for determining a parameter representative of the level of said substance in the blood on the basis of the relative values of the coefficients calculated for weighting of the first and second reference spectrum values.
M&C Folio No P53352013 3 According to another aspect of the present invention there is provided a method of monitoring the level of a predetermined substance in blood, comprising directing light from a light source onto a target area; detecting light from the source that has been reflected by or transmitted through blood in the target area; obtaining values representative of a first reference spectrum corresponding to a relatively low level of said substance in the blood; obtaining values representative of a second reference spectrum corresponding to a relatively high level of said substance in the blood; obtaining values representative of a third reference spectrum corresponding to changes in the spectral content of the detected light due to one or more factors other than the level of said substance in the blood; calculating a set of coefficients relating the spectral content of the detected light to the first, second and third spectral values relatively weighted by the coefficients; and determining a parameter representative of the level of said substance in the blood on the basis of the relative values of the coefficients calculated for weighting of the first and second reference spectrum values.
According to a further aspect of the present invention there is provided a computer readable storage medium for monitoring the level of a predetermined substance in blood by analysing the spectral content of light that has been reflected by or transmitted through the blood, the storage medium comprising a program for carrying out the following analysis steps: obtaining values representative of a first reference spectrum corresponding to a relatively low level of said substance in the blood; obtaining values representative of a second reference spectrum corresponding to a relatively high level of said substance in the blood; obtaining values representative of a third reference spectrum corresponding to changes in the spectral content of the detected light due to one or more factors other than the level of said substance in the blood; calculating a set of coefficients relating the spectral content of the detected light to the first, second and third spectral values relatively weighted by the coefficients; and determining a parameter representative of the level of said substance in the blood on the basis of the relative values of the coefficients calculated for weighting of the first and second reference spectrum values.
M&C Folio No P53352GB 4 Preferred embodiments of the claimed invention provide significant advantages in use over known techniques. Since the noise in the detection data is fairly evenly distributed, there is no need to remove the noise prior to analysing the data. It is also straightforward to determine the magnitude of the haemoglobin in the blood in order to make a subjective assessment as to the meaningfulness of the measured values in the case of SO2 monitoring. Prior art techniques actually amplify the noise content where only a small haemoglobin signal is present and this may result in meaningless SO2 values being obtained. It is also particularly advantageous if the detector is adapted to simultaneously detect light of different wavelengths that have been reflected by or transmitted through blood in the target area, to enable simultaneous analysis of the spectral content of said different wavelengths by the analyser. This enables the measurement to be made more quickly than in prior art arrangements in which detection of different wavelengths is made sequentially, and most importantly avoids any apparent change in the spectrum due to relative movement between the detector and the target area while the measurement is being effected. Where detection of all the different spectral components is being made simultaneously, any such movement will affect all the spectral components equally and does not adversely effect the measurement.
Furthermore the technique of the invention places no reliance on isobestic points, and would be valid even if the detected spectrum were decomposed into fundamental absorption peaks. By contrast prior art techniques are particularly sensitive to isobestic positioning, and the precise positioning of these points is known to change with temperature and pH, for example. Another advantage of the technique of the invention is that the input data for analysis is in the form of a set of independent coordinates (absorption versus wavelength), and it is possible to remove some of these coordinates without affecting the analysis. This would enable certain problem wavelengths (corresponding to fluorescent peaks, for example) to be eliminated, or values detected by faulty pixels in the detector pixel array to be eliminated completely. Furthermore the measurement results can be given with greater precision than with prior art techniques in which the precision is limited by the finite number of reference profiles.
M&C Folio No P53352GB 5 In one embodiment of the invention the third memory means stores values representative of substantially linear variation of at least one of said factors with wavelength. These factors may comprise several different species of melanin that exhibit approximately linear absorption characteristics in the wavelength range of interest. However, the applied technique could easily be adapted so that the third memory means stores values representative of non-linear variation of at least one of the factors with wavelength.
Preferably, in addition to calculation of coefficients relating the spectral content of the detected light to the first, second and third reference spectrum values, the calculating means also serves to calculate an offset value that is substantially invariable with wavelength.
It is also a particular advantage of the invention that is enables the simultaneous monitoring of the levels of a number of different substances in blood.
In order that the invention may be more fully understood, a preferred embodiment of SO2 measurement apparatus in accordance with the invention will now be described, by way of example, with reference to the accompanying drawings, in which: Figure 1 is a diagram of a detector assembly used in the apparatus; Figure 2 is a graph of the extinction coefficients of Hb and Hb02 against wavelength; Figure 3 is a graph of the extinction coefficients of pheomelanin and eumelanin against wavelength; and Figure 4 is a graph showing the effect of ambient fluorescent light interference on the light level detected in use of the apparatus as a function of wavelength.
Figure 1 diagrammatically shows a detector assembly for monitoring the oxygenation of blood, as used in the SO2 measurement apparatus constituting a preferred embodiment M&C Folio No P53352GB 6 of apparatus in accordance with the present invention. In such apparatus a probe is has a LED at one end for directing white light onto a target area of a patient's body or a tube carrying the patient's blood, and an optical fibre for receiving the light reflected by or transmitted through the blood in the target area and for transmitting this to a monitoring unit incorporating a spectrometer assembly. The probe is coupled to the monitoring unit by a lead incorporating the optical fibre and the necessary electrical wiring for supplying power to the LED. In practice two or more probes will be coupled to the monitoring unit, including, in one implementation, a probe for monitoring the venous absorption spectrum and a probe for monitoring the arterial absorption spectrum. In alternative implementations of the invention a substantially greater number of probes may be provided for measuring the absorption at a number of points on the patient's skin.
The transmitted or reflected light from the target area is inputted to the spectrometer assembly I by means of the optical fibre 2 and is reflected by a mirror 3 towards a splitter 4 that serves to split the light into its constituent spectral components. The spectral components of the light are then reflected by a curved mirror 5 towards a linear CCD photodetector array 6 comprising a series of pixels spaced apart along a detection axis so that spectral components of different wavelengths are detected by different pixels and electrical output signals are obtained from the photodetector 6 indicative of the relative intensities of the detected spectral components. The light transmitted or reflected by the venous blood and the arterial blood may be detected separately by a common detector assembly or by means of two separate detector assemblies. Other types of spectrometer can be used in alternative implementations of the invention.
In a typical measurement cycle of a preferred method in accordance with the invention, a "light sample" measurement is first obtained utilising the transmitted or reflected light from the target area as described above, followed by a "dark sample" measurement obtained under the same conditions as the "light sample" but with the light from the LED turned off. The output signals from the array for the dark sample are then subtracted, pixel by pixel, from the output signals from the array for the light sample.
This compensates for first and second aberrations in the detected data. The first M&C Folio No P53352GB 7 aberration is a feature of CCD electronic detectors in that they give an output even when no light is present, and this output is a function of integration time, temperature and physical properties of the individual CCD detector. The second aberration is ambient light entering the system. The light-dark sample obtained in this manner is known as a remittance spectrum, and an absorbance spectrum is obtained from the remittance spectrum by applying the following formula A = -log (Rb / Rw) on a pixel by pixel basis, where Rb is the remitted blood sample as described above, and Rw is a remitted white reference sample.
Conceptually Rw is the sample that would have been obtained by measurement of the remitted spectrum of a pure white target, although in practice such a sample is never actually measured directly, due to the complex calibration procedure used in this technique. The inclusion of the white reference sample here compensates for the non- uniform nature of various parts of the apparatus, namely the detector, the light source etc. The log transform, using the mathematical identity log (AX) = log (A) + log (X) or log (AX) = k + log(X) where k = log (A), turns scalar changes in Rw and Rb into linear shifts in the absorbance spectrum so that, if, instead true remittance being measured, a constant fraction of remittance is measured, the log curve corresponds to the true absorbance plus a (different) constant. Thus, provided that the SO2 calculation can compensate for linear shifts in the absorbance curve, it is never necessary to know the illumination levels in absolute terms, and the same result is obtained regardless of how much of the remitted light is actually collected.
The generation of reference spectra corresponding to high and low levels of oxygenation of the blood in this method is substantially the same as in the method described in WO 00/09004 in that high oxygen saturation of a sample of blood is artificially induced, after which, when stability has been reached, the current absorbance curve is taken as the high level reference spectrum, along with a corresponding SO2 value obtained from a blood gas analyser. Blood gas analysers are both invasive and destructive, but give much higher precision. The measurement step is then repeated with a sample of blood of low oxygen saturation to obtain the low level reference spectrum.
M&C Folio No P53352GB 8 Figure 2 is a graph of the light absorption by blood over a range of wavelengths expressed in terms of the extinction coefficient at each wavelength for fully deoxygenated blood Hb and fully oxygenated blood Hb02. In practice the absorption spectra, corresponding to the low level reference spectrum and the high level reference spectrum referred to above, measured for an actual patient will always be for blood that has some intermediate level of oxygenation between 0% and 100%, and the detected values obtained for venous and arterial blood will correspond to two different levels of oxygenation between 0% and 100%. The function of the apparatus is to determine what levels of oxygenation correspond to the detected spectral values.
Referring to the two absorption spectra 10 and 11 of Figure 2 corresponding to the extinction coefficients of Hb and Hb02, it will be appreciated that these exhibit various peak values and additionally a number of wavelengths, that is the so-called isobestic wavelengths, at which the light absorption of the blood is independent of the degree of oxygenation. In analysing the detected spectral values obtained with a particular sample of blood, it is necessary to determine the relative contributions to the absorption spectrum of deoxygenated haemoglobin Hb and oxygenated haemoglobin Hb02. It is known to match the measured absorption, reflectance or transmission spectrum against two or more reference spectra representing different predetermined levels of blood oxygenation such that the match yields a measure of actual blood oxygen saturation.
It may be shown that, for a medium consisting of several absorbers A1, A2, A3 etc., the resulting absorption spectrum takes the form: A(X) 1a(cleJQ) +c2e2() +c3e3Q)+ ) where Ia is the average photon path length, ci, c2, c3. .. are the molar concentrations of the absorbing species, and e1(X), e2(X) , e3(?)... are the extinction coefficients of the absorbers expressed as functions of wavelength.
M&C Folio No P53352GB 9 In the measurements made by the apparatus of the invention we are concerned with three principle absorbing species, namely melanin (actually several different species in various proportions), Hb02 and Hb.
The extinction coefficients of these absorbers shown in Figure 2 and 3 (Figure 3 showing separately the extinction coefficients of pheomelanin and eumelanin) give rise to the familiar double hump absorption spectra between 500 nm and 600 nm.
It is known that in tissue the melanin species vary but importantly all exhibit approximately linear absorption characteristics within the wavelength range of interest.
It is therefore possible to model the total melanin contribution as a linear function of wavelength: AmQ) = mm). + c m It is therefore possible to model the detected absorption spectrum in terms of four coefficients mm, cm, cHbo2 and cub as follows: A(A) = C m + rnm + cHbO2.eHbo2Q) + cljb.eHb(?) where eHbo2Q) and eHb(X) are the extinction functions of Hb02 and Hb shown in Figure 2, and mm, cm, cHbo2 and cHb are the set of coefficients characterising the sample.
Absorbance as a measurement is independent of integration time. However it is convenient to alter the integration time to optimise the dynamic range of the received signal whilst still using a white light reference derived at a fixed integration time. This has the effect of introducing an offset in the absorbance curve approximating to the logarithm of the integration time ratios.
The other significant variable to be aware of relates to the relative concentrations of the three principle absorbers. For lower haemoglobin concentrations the absorption peaks are flatter.
M&C Folio No P53352GB 10 The analysis arrived at in the analyser of the apparatus of the present invention uses a Levenberg-Marquardt algorithm to simpli the analysis process by directly decomposing the observed spectra into the four required coefficients. Such an algorithm is discussed in Marquardt, D. M., "An Algorithm for Least Squares Estimation of Nonlinear Parameters", I Soc. md. App!. Math. 11,431-441 (1963). The method is also described in "Numerical Recipes in C++, The Art of Scientific Computing", Second Edition, Cambridge University Press 1988- 2002 by William H. Press, Saul A. Teukoisky, William T. Vetterling, Brian P. Flannery, Chapter 15.5, pages 686 to 694. The method uses an elegant mathematical technique to perform multi- variate non-linear least squares fitting. The algorithm requires a definition of all the individual absorption functions into which the sample curve is to be split and provides the relative amplitudes of these components which best match the detected absorption spectrum of the sample. Other algorithms can also be used for such analysis, such as the Newton Raphson algorithm, as described in "Numerical Recipes in C++, The Art of Scientific Computing", Chapter 9.4, pages 366 to 373.
Since the oxygen saturation SO2 is by definition the ratio of Hb02 to total Hb02 + Hb it follows that it can then be directly calculated from the coefficients without needing to apply the normalisation required in prior art techniques.
Since the noise in the data sets characterising the detected absorption spectrum is normally distributed there is no requirement to remove it prior to fitting. Noisy and filtered versions of the same data converge to the same solution.
By extracting the magnitude of the haemoglobin contribution to the detected absorption spectrum it is possible to make a subjective decision as to its usefulness. This is an improvement over prior art techniques which, by manipulating (normalising) the spectrum, actually amplify the noise content in the case where only a small haemoglobin signal is present. This could potentially lead to meaningless SO2 values in tissue samples where some semblance of fit still exists.
M&C Folio No P53352GB 11 The algorithm treats the input data characterising the detected absorption spectrum as a set of independent coordinates (absorption versus wavelength). Furthermore it is possible to remove certain coordinates without affecting the convergence. This could be useful in eliminating problem wavelengths (fluorescent etc) or building a bad pixel list if it becomes commercially prudent to do so.
The technique places no reliance on isobestics points, etc. and will be equally valid should it be required to decompose the spectra into fundamental absorption peaks. The key difference between the preferred method of the invention and the prior art method of WO 00/09004 relates to the manner in which the SO2 estimation is obtained from a given run time absorbance curve. The method of the invention relies on designing a mathematical model for absorbance, and using this model to calculate concentrations for Hb, Hb02, melanin, dc shift values and any other analyte that has a characteristic spectrum. On the other hand the prior method of WO 00/09004 relies on the numerical values at the isobestic points to allow dc offset and melanin to be compensated for, and on comparing the measured curve to all 101 possible mathematically generated SO2 curves from 0 to 100, the right curve being that which gives the least sum of pixel by pixel differences between the reference curve and the measured curve. In such prior methods, an error in the measurement of those few pixels around the isobestic points could throw out the whole calculation. By contrast, in use of the method of the invention, those points have no more weighting than all the other pixels.
Various modifications of the above described analysis are also possible within the scope of the invention to take account of different applications. In particular the technique can be adapted for the purpose of detecting different analytes in blood other than oxygen.
For example one possibility would be for the technique to be modified to detect the level of carbon monoxide in blood, that is the level of haemoglobin bound to carbon monoxide as HbCO. The technique could also be adapted to compensate for the presence of interferents other than melanin. A particular example would be to add a term to the algorithm enabling the interferents due to fluorescent lighting, which can have the effect of disrupting the absorbance spectrum as shown in Figure 4 for example, to be compensated so as to either improve the signal quality or identify possible error M&C Folio No P53352GB 12 conditions (or a combination of the two). Advantageously the technique can be used to simultaneously measure the level of three or more analytes in the blood.
Furthermore, since the linear melanin model already discussed with reference to Figure 2 is only an approximation, the technique could be modified to include a non-linear melanin function.
The part of the detected absorption spectrum that is usually used for the analysis is in the blue-green to yellow-red areas, but the unique signatures of the Hb02 and Hb spectra extend right down to the blue part of the visible spectrum, and this area could potentially be used in the analysis provided that the detector is sensitive enough to resolve the reduction in signal due to the increased extinction coefficient in this area.
In more complex models it is possible to add restraints to the parameters to prevent convergence to unrealistic solutions.
Claims (17)
- M&C Folio No P53352GB 1 3 CLAIMS: I. Apparatus for monitoring the level ofa predetermined substance in blood, comprising a light source for directing light onto a target area; a detector for detecting light from the source that has been reflected by or transmitted through blood in the target area; an analyser for analysing the spectral content of the detected light, the analyser comprising first memory means for storing values representative of a first reference spectrum corresponding to a relatively low level of said substance in the blood; second memory means for storing values representative of a second reference spectrum corresponding to a relatively high level of said substance in the blood; third memory means for storing values representative of a third reference spectrum corresponding to changes in the spectral content of the detected light due to one or more factors other than the level of said substance in the blood; calculating means for calculating a set of coefficients relating the spectral content of the detected light to the first, second and third reference spectrum values relatively weighted by the coefficients; and determining means for determining a parameter representative of the level of said substance in the blood on the basis of the relative values of the coefficients calculated for weighting of the first and second reference spectrum values.
- 2. Apparatus according to claim 1, wherein the third memory means stores values representative of substantially linear variation of at least one of said factors with wavelength.
- 3. Apparatus according to claim I or 2, wherein the third memory means stores values representative of non-linear variation of at least one of said factors with wavelength.M&C Folio No P53352GB 14
- 4. Apparatus according to claim 1, 2 or 3, wherein the calculating means serves to calculate coefficients relating the spectral content of the detected light to the first, second and third reference spectrum values and an offset value that is substantially invariable with wavelength.
- 5. Apparatus according to any preceding claim, wherein the third memory means stores values representative of changes in the absorbance of the light with wavelength due to melanin.
- 6. Apparatus according to any preceding claim, wherein the third memory means stores values representative of changes in the spectral content of the detected light due to ambient light interference.
- 7. Apparatus according to any preceding claim, wherein further memory means are provided for storing values representative of a further reference spectrum corresponding to the presence of a further substance in the blood.
- 8. Apparatus according to any preceding claim, wherein the detector is adapted to simultaneously detect light of different wavelengths that have been reflected by or transmitted through blood in the target area, to enable simultaneous analysis of the spectral content of said different wavelengths by the analyser.
- 9. Apparatus according to any preceding claim, wherein the light source includes at least one light-emitting diode.
- 10. Apparatus according to any preceding claim, wherein the light source is adapted to direct multiwavelength light onto the target area, and the detector includes a splitter for splitting the detected light into its spectral components.
- 11. Apparatus according to claim 10, wherein the detector includes a photodetector array for providing electrical signals indicative of the relative intensities of the spectral components.M&C Folio No P53352GB 1 5
- 12. Apparatus according to any preceding claim, wherein the detector includes one or more optical fibres for receiving the detected light.
- 13. A method of monitoring the level of a predetermined substance in blood, comprising: directing light from a light source onto a target area; detecting light from the source that has been reflected by or transmitted through blood in the target area; obtaining values representative of a first reference spectrum corresponding to a relatively low level of said substance in the blood; obtaining values representative of a second reference spectrum corresponding to a relatively high level of said substance in the blood; obtaining values representative of a third reference spectrum corresponding to changes in the spectral content of the detected light due to one or more factors other than the level of said substance in the blood; calculating a set of coefficients relating the spectral content of the detected light to the first, second and third spectral values relatively weighted by the coefficients; and determining a parameter representative of the level of said substance in the blood on the basis of the relative values of the coefficients calculated for weighting of the first and second reference spectrum values.
- 14. A computer readable storage medium for monitoring the level of a predetermined substance in blood by analysing the spectral content of light that has been reflected by or transmitted through the blood, the storage medium comprising a program for carrying out the following analysis steps: obtaining values representative of a first reference spectrum corresponding to a relatively low level of said substance in the blood; obtaining values representative of a second reference spectrum corresponding to a relatively high level of said substance in the blood; M&C Folio No P53352GB 16 obtaining values representative of a third reference spectrum corresponding to changes in the spectral content of the detected light due to one or more factors other than the level of said substance in the blood; calculating a set of coefficients relating the spectral content of the detected light to the first, second and third spectral values relatively weighted by the coefficients; and determining a parameter representative of the level of said substance in the blood on the basis of the relative values of the coefficients calculated for weighting of the first and second reference spectrum values.
- 15. Apparatus for monitoring the level of a predetermined substance in blood, the apparatus being substantially as hereinbefore described with reference to the accompanying drawings.
- 16. A method of monitoring the level of a predetermined substance in blood, the method being substantially as hereinbefore described with reference to the accompanying drawings.
- 17. A computer readable storage medium for monitoring the level of a predetermined substance in blood, the storage medium being substantially as hereinbefore described with reference to the accompanying drawings.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0505101A GB2424270A (en) | 2005-03-14 | 2005-03-14 | Optical monitoring of predetermined substances in blood |
PCT/EP2006/060639 WO2006097437A1 (en) | 2005-03-14 | 2006-03-10 | Monitoring of predetermined substances in blood |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0505101A GB2424270A (en) | 2005-03-14 | 2005-03-14 | Optical monitoring of predetermined substances in blood |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0505101D0 GB0505101D0 (en) | 2005-04-20 |
GB2424270A true GB2424270A (en) | 2006-09-20 |
Family
ID=34508956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0505101A Withdrawn GB2424270A (en) | 2005-03-14 | 2005-03-14 | Optical monitoring of predetermined substances in blood |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2424270A (en) |
WO (1) | WO2006097437A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7725146B2 (en) | 2005-09-29 | 2010-05-25 | Nellcor Puritan Bennett Llc | System and method for pre-processing waveforms |
US20070100220A1 (en) | 2005-10-28 | 2007-05-03 | Baker Clark R Jr | Adjusting parameters used in pulse oximetry analysis |
US8140272B2 (en) | 2008-03-27 | 2012-03-20 | Nellcor Puritan Bennett Llc | System and method for unmixing spectroscopic observations with nonnegative matrix factorization |
US8437822B2 (en) | 2008-03-28 | 2013-05-07 | Covidien Lp | System and method for estimating blood analyte concentration |
US8862194B2 (en) | 2008-06-30 | 2014-10-14 | Covidien Lp | Method for improved oxygen saturation estimation in the presence of noise |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6859658B1 (en) * | 1998-11-18 | 2005-02-22 | Lea Medizintechnik Gmbh | Device for non-invasively detecting the oxygen metabolism in tissues |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5564417A (en) * | 1991-01-24 | 1996-10-15 | Non-Invasive Technology, Inc. | Pathlength corrected oximeter and the like |
GB9216431D0 (en) | 1992-08-01 | 1992-09-16 | Univ Swansea | Optical monitoring or measuring artefact suppression |
WO2000001294A1 (en) | 1998-07-04 | 2000-01-13 | Whitland Research Limited | Non-invasive measurement of blood analytes |
EP1104254A2 (en) | 1998-08-13 | 2001-06-06 | Whitland Research Limited | Optical device |
-
2005
- 2005-03-14 GB GB0505101A patent/GB2424270A/en not_active Withdrawn
-
2006
- 2006-03-10 WO PCT/EP2006/060639 patent/WO2006097437A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6859658B1 (en) * | 1998-11-18 | 2005-02-22 | Lea Medizintechnik Gmbh | Device for non-invasively detecting the oxygen metabolism in tissues |
Also Published As
Publication number | Publication date |
---|---|
WO2006097437A1 (en) | 2006-09-21 |
GB0505101D0 (en) | 2005-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2244111C (en) | Method and apparatus for multi-spectral analysis in noninvasive nir spectroscopy | |
US4446871A (en) | Optical analyzer for measuring a construction ratio between components in the living tissue | |
US5360004A (en) | Non-invasive determination of analyte concentration using non-continuous radiation | |
US5372135A (en) | Blood constituent determination based on differential spectral analysis | |
US5692503A (en) | Method for noninvasive (in-vivo) total hemoglobin, oxyhemogolobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin concentration determination | |
US5725480A (en) | Non-invasive calibration and categorization of individuals for subsequent non-invasive detection of biological compounds | |
DK2034893T3 (en) | Measurement of tissue oxygenation | |
US5533509A (en) | Method and apparatus for non-invasive measurement of blood sugar level | |
US6927843B2 (en) | Non-invasive measurement of skin bilirubin level | |
AU716192B2 (en) | Method and apparatus for multi-spectral analysis in noninvasive infrared spectroscopy | |
JP5175179B2 (en) | Improved blood oxygenation monitoring method by spectrophotometry | |
US20050250998A1 (en) | Compensation of human variability in pulse oximetry | |
US8175665B2 (en) | Method and apparatus for spectroscopic tissue analyte measurement | |
US20130310668A1 (en) | System, method and computer program product for optical measurement of blood parameters | |
WO2004010844A2 (en) | Method for spectrophotometric blood oxygenation monitoring | |
JP2009507569A (en) | Continuous spectroscopic measurement of total hemoglobin | |
JPH10318915A (en) | Measuring device of concentration of object under spectrophotometric analysis | |
WO2006097437A1 (en) | Monitoring of predetermined substances in blood | |
EP1178750A1 (en) | Method for improving calibration of a blood monitoring instrument | |
EP0623307A1 (en) | Non-invasive determination of constituent concentration using non-continuous radiation | |
Pathirage et al. | Removing subject dependencies on non-invasive blood glucose measurement using hybrid techniques | |
Saptari et al. | Sensitivity analysis of near-infrared glucose absorption signals: toward noninvasive blood glucose sensing | |
JP2003149145A (en) | Non-invasive glucose level measuring device | |
JP2007506522A (en) | Measurement of blood oxygen saturation | |
JPH11178813A (en) | Method and device for quantitatively determining glucose concentration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |